Theralase® Bladder Cancer Clinical Study
Our Anti-Cancer technology has been successfully evaluated in a Phase 1b Clinical Study for Non-Muscle Invasive Bladder Cancer ("NMIBC"). Theralase® has now launched Phase II NMIBC Clinical Study, with five patients treated at the world-renowned Princess Margaret Cancer Centre in Toronto, Canada.
Our TLD-1433 PhotoDynamic Compound (“PDC”) has proven to be highly toxic to bladder cancer cells when activated by light, producing a 100% kill rate at very low concentrations.
In the following video Dr. Girish Kulkarni MD, Surgeon-scientist affiliated with the Department of Surgery, Faculty of Medicine at the University of Toronto discusses the successful completion of this clinical study.
IMPORTANT INFORMATION FOR PATIENTS
If you are a patient interested in participating in the study, please download the list of all the active sites currently recruiting patients. Please have your healthcare provider contact the principal investigator before you make any decisions. Please note that Theralase cannot provide any additional information on sites currently recruiting patients.